Study Name:
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets (OCEAN-2)
Targeted Disease(s):
Other|Pulmonary Fibrosis
Purpose of Study:
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.
Study Dates:
September 30, 2026 - August 31, 2027
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Trevi Therapeutics
Sponsors:
Trevi Therapeutics
ClinicalTrails.gov Identifier:
NCT07868419
